Armistice Capital LLC recently announced the acquisition of new stake in Cleveland BioLabs Inc. (NASDAQ:CBLI). The institutional investor has increased its shareholding in the Healthcare company to 0.52 million shares with purchase of 0.52 million shares. This fresh investment now brings its stake to 4.55% valued currently at $1.06 million. In addition, The Vanguard Group, Inc. raised its holdings by 16107.0 to 51060.0 shares. And National Asset Management, Inc. has lifted its position by 7.25% or 1150.0 shares – to 17013.0 shares.
With over 0.52 million Cleveland BioLabs Inc. (CBLI) shares trading Thursday and a closing price of $2.24 on the day, the dollar volume was approximately $1.16 million. The shares have shown a positive weekly performance of 30.23% and its price on 07/02/20 lost nearly 0.00%. Currently, there are 11.35M common shares owned by the public and among those 5.58M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: Several analysts who have offered their price forecasts for CBLI have a consensus price objective of $40.00. The analysts have set the share’s price value over the next 12 months at a high of $40.00 and a low of $40.00 should the stock experience a downside. Incidentally, analysts’ outlook for the Cleveland BioLabs Inc. with estimated low will see the stock gain 94.4% over that period. But an upside of 94.4% will see the stock hit the forecast high price target while mean target price for the stock is $40.00.
Insiders at the company have nil transactions over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC).
The top 3 mutual fund holders in Cleveland BioLabs Inc. are Vanguard Extended Market Index Fu, Fidelity Extended Market Index Fu, and Fidelity Nasdaq Composite Index F. Vanguard Extended Market Index Fu owns 51060.0 shares of the company’s stock, all valued at over $0.1 million. The company has a total holdings of about 0.45% of the shares outstanding. Fidelity Extended Market Index Fu has total holdings of 9814.0 shares valued at over $20119.0 and representing 0.09% of the shares outstanding. Fidelity Nasdaq Composite Index F has total holdings to over 5822.0 shares at a value of $11935.0. Fidelity Nasdaq Composite Index F now owns shares totaling to 0.05% of the shares outstanding.
Shares of Cleveland BioLabs Inc. (NASDAQ: CBLI) opened at $2.22, down -$0.02 from a prior closing price of $2.24. However, the script later closed the day at $2.24, down 0.00%. The company’s stock has a 5-day price change of 30.23% and 46.41% over the past three months. CBLI shares are trading 272.09% year to date (YTD), with the 12-month market performance up to 51.35% higher. It has a 12-month low price of $0.50 and touched a high of $5.00 over the same period. Currently, 0.52 million shares have been traded, compared to an average intraday trading volume of 1.25 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 19.27%, 20.13%, and 49.18% respectively.
Institutional ownership of Cleveland BioLabs Inc. (NASDAQ: CBLI) shares accounts for 3.20% of the company’s 11.35M shares outstanding. Mutual fund holders own 1.14%, while other institutional holders and individual stakeholders account for 7.48% and 0.65% respectively.
It has a market capitalization of $28.90M and a beta (3y monthly) value of 1.01. The stock’s earnings-per-share (ttm) stands at -$0.21. The company has a Quick Ratio of 1.70. Price movements for the stock have been influenced by the stock’s volatility, which stands at 47.87% over the week and 18.84% over the month.
Looking at the support for the CBLI, a number of firms have released research notes about the stock. Oppenheimer stated their Perform rating for the stock in a research note on January 24, 2014. Cantor Fitzgerald coverage for the Cleveland BioLabs Inc. (CBLI) stock in a research note released on March 21, 2013 offered a Buy rating with a price target of $4. Oppenheimer was of a view on December 06, 2012 that the stock is Outperform, while Burrill Institutional Research gave the stock Mkt Outperform rating on December 04, 2012 $4. Wedbush on their part issued Outperform rating on February 02, 2011.